Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2006 1
2007 3
2008 2
2009 11
2010 8
2011 9
2012 15
2013 15
2014 6
2015 6
2016 5
2017 3
2018 2
2019 4
2020 6
2021 7
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

93 results

Results by year

Filters applied: . Clear all
Page 1
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trněný M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Marcus R, et al. Among authors: rufibach k. N Engl J Med. 2017 Oct 5;377(14):1331-1344. doi: 10.1056/NEJMoa1614598. N Engl J Med. 2017. PMID: 28976863 Free article. Clinical Trial.
Estimands and Complex Innovative Designs.
Collignon O, Schiel A, Burman CF, Rufibach K, Posch M, Bretz F. Collignon O, et al. Among authors: rufibach k. Clin Pharmacol Ther. 2022 Dec;112(6):1183-1190. doi: 10.1002/cpt.2575. Epub 2022 Mar 29. Clin Pharmacol Ther. 2022. PMID: 35253205 Free PMC article. Review.
Estimands in hematologic oncology trials.
Sun S, Weber HJ, Butler E, Rufibach K, Roychoudhury S. Sun S, et al. Among authors: rufibach k. Pharm Stat. 2021 Jul;20(4):793-805. doi: 10.1002/pst.2108. Epub 2021 Mar 8. Pharm Stat. 2021. PMID: 33686762
Modified study designs to expand treatment options in personalised oncology: a multistakeholder view.
Le Tourneau C, André F, Helland Å, Mileshkin L, Minnaard W, Schiel A, Taskén K, Thomas DM, Veronese ML, Durán-Pacheco G, Leyens L, Rufibach K, Thomas M, Krämer A. Le Tourneau C, et al. Among authors: rufibach k. Eur J Cancer. 2023 Nov;194:113278. doi: 10.1016/j.ejca.2023.113278. Epub 2023 Aug 4. Eur J Cancer. 2023. PMID: 37820553 Free article. Review.
Principal stratum strategy: Potential role in drug development.
Bornkamp B, Rufibach K, Lin J, Liu Y, Mehrotra DV, Roychoudhury S, Schmidli H, Shentu Y, Wolbers M. Bornkamp B, et al. Among authors: rufibach k. Pharm Stat. 2021 Jul;20(4):737-751. doi: 10.1002/pst.2104. Epub 2021 Feb 23. Pharm Stat. 2021. PMID: 33624407 Clinical Trial.
A multistate model for early decision-making in oncology.
Beyer U, Dejardin D, Meller M, Rufibach K, Burger HU. Beyer U, et al. Among authors: rufibach k. Biom J. 2020 May;62(3):550-567. doi: 10.1002/bimj.201800250. Epub 2019 Jul 16. Biom J. 2020. PMID: 31310368
Estimands for overall survival in clinical trials with treatment switching in oncology.
Manitz J, Kan-Dobrosky N, Buchner H, Casadebaig ML, Degtyarev E, Dey J, Haddad V, Jie F, Martin E, Mo M, Rufibach K, Shentu Y, Stalbovskaya V, Sammi Tang R, Yung G, Zhou J. Manitz J, et al. Among authors: rufibach k. Pharm Stat. 2022 Jan;21(1):150-162. doi: 10.1002/pst.2158. Epub 2021 Oct 3. Pharm Stat. 2022. PMID: 34605168
93 results